# Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Canonical URL: https://biopharmsignal.com/news/IPSC/century-therapeutics-to-present-at-h-c-wainwright-27th-annual-global-investment--701c5f6d
Ticker: IPSC
Company: Century Therapeutics
Source: Century Therapeutics
Published: 2025-08-22 12:00 EST
## Summary

Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing...

## Article Body
Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. In addition, members of management will be available for meetings with investors at the conference from September 9-10, 2025, in New York, NY.

The on-demand webcast of the company presentation will be available beginning at 7:00 a.m. ET on Friday, September 5, 2025, on the Investors page of Century’s website at www.centurytx.com . The webcast will be archived on the company’s website for at least 30 days.

About Century Therapeutics Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company leveraging its expertise in cellular reprogramming, genetic engineering, and manufacturing to develop cell therapies with the potential to provide meaningful advantages over existing cell therapies. Century’s genetically engineered, iPSC-derived cell therapy pipeline includes programs designed to address autoimmune diseases and cancers. Century believes its commitment to developing off-the-shelf cell therapies will expand patient access and provide an opportunity to advance the course of autoimmune disease and cancer care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

For More Information:

Century Therapeutics Douglas Carr Senior Vice President, Finance investor.relations@centurytx.com

JPA Health Sarah McCabe smccabe@jpa.com
## Recent Company News
- 2026-07-09 12:00 EST — [Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026](https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentations-of-cnty-813-preclinical-dat-b81a8a73) — Source: Century Therapeutics
- 2026-06-08 20:05 EST — [New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026](https://biopharmsignal.com/news/IPSC/new-cnty-813-preclinical-data-demonstrate-durable-glucose-control-immune-evasion-e65eb4fc) — Source: Century Therapeutics
- 2026-05-13 12:00 EST — [Century Therapeutics Reports First Quarter Financial Results and Business Updates](https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-first-quarter-financial-results-and-business-update-c4d76676) — Source: Century Therapeutics
- 2026-04-30 20:05 EST — [Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions](https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentation-of-cnty-813-preclinical-data-0932a2d5) — Source: Century Therapeutics
- 2026-03-12 12:00 EST — [Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates](https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-full-year-2025-financial-results-and-business-updat-7b62a847) — Source: Century Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)